About pralsetinib
RET kinase inhibitor
Used for
- Treats certain advanced RET fusion-positive lung cancers.
- Treats advanced or metastatic RET-altered thyroid cancers when radioactive iodine is unsuitable or ineffective.
Usual adult dose
400 mg by mouth once daily on an empty stomach; continue until disease worsens or side effects become unacceptable.
Common side effects
- Low blood-cell counts
- High blood pressure
- Liver test abnormalities
- Constipation, diarrhea, or fatigue
Important warnings
- Can cause serious lung inflammation, liver injury, bleeding, or high blood pressure.
- May impair wound healing; treatment may need pausing before and after surgery.
- Can harm an unborn baby; effective contraception is required during treatment and afterward.
- Avoid strong CYP3A inhibitors or inducers and certain stomach-acid medicines when possible.
Pregnancy
May cause fetal harm; avoid during pregnancy. Use effective contraception during treatment and for two weeks afterward.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong CYP3A inhibitors can raise drug levels.
- Strong CYP3A inducers can lower drug levels.
- Acid-reducing medicines may decrease absorption.
- May affect levels of sensitive CYP3A substrates.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.